Bruns I - Search Results

1

Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.

Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, von Haeseler A, Gattermann N, Haas R, Kronenwett R. Diaz-Blanco E, et al. Among authors: bruns i. Leukemia. 2007 Mar;21(3):494-504. doi: 10.1038/sj.leu.2404549. Epub 2007 Jan 25. Leukemia. 2007. PMID: 17252012

2

Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.

Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R, Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R. Bruns I, et al. Haematologica. 2008 Mar;93(3):347-55. doi: 10.3324/haematol.12081. Epub 2008 Feb 11. Haematologica. 2008. PMID: 18268278 Free article.

3

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.

Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, Neumann F. Bruennert D, et al. Among authors: bruns i. Leukemia. 2009 May;23(5):983-5. doi: 10.1038/leu.2008.337. Epub 2008 Dec 4. Leukemia. 2009. PMID: 19052557 No abstract available.

4

The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.

Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, Buest S, Bruennert D, Huenerlituerkoglu AN, Stoecklein NH, Singh R, Zerbini LF, Jäger M, Kobbe G, Gattermann N, Kronenwett R, Brors B, Haas R. Bruns I, et al. Leukemia. 2009 May;23(5):892-9. doi: 10.1038/leu.2008.392. Epub 2009 Jan 22. Leukemia. 2009. PMID: 19158832

5

Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.

Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, Gattermann N, Kobbe G, Germing U, Lyko F, Haas R, Schroeder T. Geyh S, et al. Among authors: bruns i. Leukemia. 2013 Sep;27(9):1841-51. doi: 10.1038/leu.2013.193. Epub 2013 Mar 29. Leukemia. 2013. PMID: 23797473

6

A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.

Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hübel K, Haas R, Kobbe G. Bruns I, et al. Transfusion. 2006 Feb;46(2):180-5. doi: 10.1111/j.1537-2995.2006.00699.x. Transfusion. 2006. PMID: 16441592 Clinical Trial.

7

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.

Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G. Fenk R, et al. Among authors: bruns i. Leuk Lymphoma. 2007 Dec;48(12):2345-51. doi: 10.1080/10428190701694194. Leuk Lymphoma. 2007. PMID: 18067009

8

Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.

Bruns I, Cadeddu RP, Brueckmann I, Fröbel J, Geyh S, Büst S, Fischer JC, Roels F, Wilk CM, Schildberg FA, Hünerlitürkoglu AN, Zilkens C, Jäger M, Steidl U, Zohren F, Fenk R, Kobbe G, Brors B, Czibere A, Schroeder T, Trumpp A, Haas R. Bruns I, et al. Blood. 2012 Sep 27;120(13):2620-30. doi: 10.1182/blood-2011-04-347484. Epub 2012 Apr 18. Blood. 2012. PMID: 22517906 Free PMC article.

9

Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.

Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Gräf T, Rohr UP, Bork S, Kronenwett R, Haas R, Kobbe G. Steidl U, et al. Among authors: bruns i. Bone Marrow Transplant. 2005 Jan;35(1):33-6. doi: 10.1038/sj.bmt.1704702. Bone Marrow Transplant. 2005. PMID: 15531906 Clinical Trial.

10

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, Haas R, Kobbe G. Safaian NN, et al. Among authors: bruns i. Leuk Res. 2009 Feb;33(2):348-50. doi: 10.1016/j.leukres.2008.04.017. Epub 2008 Jun 24. Leuk Res. 2009. PMID: 18573526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters